Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Get some AXSM= 2 BIG PHASE 3 READOUT THIS MONTH=10 BAGGER Potential. more infos below = RALLYYYYYY
AXSM (MC $120 M) (Cash $40 M) Shares Out 25.4 M // 7x Phase 3 programs in various indications targeting billion dollar markets ..2x Phase 3 readout expected within THIS MONTH = Could run to $20+ .Sabby Management just bought 1.4 Million shares a few days ago which is a good sign .GL
Axsome Therapeutics (AXSM)
Market Cap: $120 M
Cash $40 M
Price: $4.75
Shares Out : 25.4 M ( 16+ Million shares held alone by Management & Institutions)
Presentation from mid November (see slide 36 for upcoming milestones)
http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_13%20Nov%202017.pdf
Anticipated Near-Term Clinical Milestones
• Clinical Trial Readouts:
Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018)
Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018)
Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H 2018)
runup to phase 3 results has just begun...GL
"JPMorgan Chase & Co. increased its position in Axsome Therapeutics Inc (NASDAQ:AXSM) by 1.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,459,117 shares of the company’s stock after buying an additional 23,229 shares during the period. JPMorgan Chase & Co. owned 6.18% of Axsome Therapeutics worth $8,026,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the stock. Susquehanna International Group LLP purchased a new stake in shares of Axsome Therapeutics in the second quarter worth about $188,000. Goldman Sachs Group Inc. raised its position in Axsome Therapeutics by 118.7% during the second quarter. Goldman Sachs Group Inc. now owns 67,618 shares of the company’s stock valued at $372,000 after purchasing an additional 36,698 shares during the period. Finally, Sphera Funds Management LTD. raised its position in Axsome Therapeutics by 24.9% during the second quarter. Sphera Funds Management LTD. now owns 501,000 shares of the company’s stock valued at $2,756,000 after purchasing an additional 100,000 shares during the period. Institutional investors own 23.62% of the company’s stock."
5 Top Biotech Penny Stocks to Buy with Huge Catalysts in January 2018...December 21, 2017
https://moneymorning.com/2017/12/21/5-top-biotech-penny-stocks-to-buy-with-huge-catalysts-in-january-2018/
Currently trading at $4.85, Manhattan-based Axsome Therapeutics Inc. (Nasdaq: AXSM) makes drugs to treat depression, Alzheimer's disease, and chronic pain.
Unlike other biotech penny stocks, shares of AXSM aren't "all in" on just one drug's results.
Axsome has at least three different drugs in clinical trial testing, meaning it has a greater chance of having at least one of its drugs pass. This makes shares of AXSM less risky than a biotech penny stock with only one drug in development.
Specifically, we're going to focus on Axsome's AXS-02 drug, which is in two separate phase 3 clinical trials to treat complex regional pain syndrome and knee osteoarthritis associated with bone marrow lesions. The results for these two clinical trials are expected in late December or early January.
If the AXS-02 drug passes phase 3 clinical trials, the stock could jump significantly.
The company also has a second drug, AXS-05, currently in phase 3 clinical trials for the treatment of treatment-resistant depression. Those results are expected sometime in the first half of 2018, so it's likely that AXS-02's results will come out first.
The next company we'll show you is the cheapest on this list…
$10++ if phase 3 results is successful
Biotech Penny Stocks to Buy for January, No. 4: Axsome Therapeutics Inc....December 21, 2017
https://moneymorning.com/2017/12/21/5-top-biotech-penny-stocks-to-buy-with-huge-catalysts-in-january-2018/
Specifically, we're going to focus on Axsome's AXS-02 drug, which is in two separate phase 3 clinical trials to treat complex regional pain syndrome and knee osteoarthritis associated with bone marrow lesions. The results for these two clinical trials are expected in late December or early January.
$5++ imminent
2 BIG P3 READOUT THIS MONTH=$$$$$ GET SOME AXSM
AXSM (MC $120 M) (Cash $40 M) Shares Out 25.4 M // 7x Phase 3 programs in various indications targeting billion dollar markets ..2x Phase 3 readout expected within THIS MONTH = Could run to $20+ .Sabby Management just bought 1.4 Million shares a few days ago which is a good sign .GL
Axsome Therapeutics (AXSM)
Market Cap: $120 M
Cash $40 M
Price: $4.75
Shares Out : 25.4 M ( 16+ Million shares held alone by Management & Institutions)
Presentation from mid November (see slide 36 for upcoming milestones)
http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_13%20Nov%202017.pdf
Anticipated Near-Term Clinical Milestones
• Clinical Trial Readouts:
Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018)
Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018)
Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H 2018)
Axsome Therapeutics Inc (AXSM) Stake Owned by Sabby Management, LLC...Dec 4th, 2017
https://www.themarketsdaily.com/2017/12/04/axsome-therapeutics-inc-axsm-stake-owned-by-sabby-management-llc.html
AXSM= 2 BIG P3 READOUT THIS MONTH=$$$$$
AXSM (MC $120 M) (Cash $40 M) Shares Out 25.4 M // 7x Phase 3 programs in various indications targeting billion dollar markets ..2x Phase 3 readout expected within THIS MONTH =HUGE Upside Potential on this undiscovered low float gem .GL
Axsome Therapeutics (AXSM)
Market Cap: $120 M
Cash $40 M
Price: $4.75
Shares Out : 25.4 M ( 16+ Million shares held alone by Management & Institutions)
Presentation from mid November (see slide 36 for upcoming milestones)
http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_13%20Nov%202017.pdf
Anticipated Near-Term Clinical Milestones
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (4Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
AXSM= 2 BIG P3 READOUT THIS MONTH=$$$$$
AXSM (MC $120 M) (Cash $40 M) Shares Out 25.4 M // 7x Phase 3 programs in various indications targeting billion dollar markets ..2x Phase 3 readout expected within THIS MONTH =HUGE Upside Potential on this undiscovered low float gem .GL
Axsome Therapeutics (AXSM)
Market Cap: $120 M
Cash $40 M
Price: $4.75
Shares Out : 25.4 M ( 16+ Million shares held alone by Management & Institutions)
Presentation from mid November (see slide 36 for upcoming milestones)
http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_13%20Nov%202017.pdf
Anticipated Near-Term Clinical Milestones
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (4Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
IGXT (MC $48 M) Great time to load up guys after they resubmit the NDA early this Week .
Market Cap : US$48 Million / Cash US$8.2 million /very low burn-rate of ~$700K a Quarter =Cash untill 2020+ EXCLUDING payments from new partnerships ,profitability expected quickly with approval for Rizaport and Tadalafil both approval expected in 2018, if everything goes well then this stock could run to $10 even then it wouldnt be expensive = ONE OF MOST ATTRACTIVE AND UNDERPRICED PHARMA STOCK YOU CAN GET AT THIS TIME .I LOVE IT
Intelgenx (IGXT)
Markt-Cap $48 Million
Cash 8.1 Million
Price: $0.73
FDA Decision for Rizaport(Migraine) in Q2/2018 (Peak Sales $60-80 Million)
NDA submission for Tadalafil (erectile dysfunction) this Quarter >> FDA approval in 2H 2018 (Peak Sales $150++ Million)
Start Phase 2a for Montulukast (Alzheimer disease) this Quarter >> Phase 2a Results in 1H/2018 (Potential BLOCKBUSTER Drug)
Opioid dependence drug partnered with Par Pharma >> FDA approval depends on patent ruling (Peak Sales $100++ Million) 30-Month Stay already expired
MEGA Pipeline
http://s2.q4cdn.com/790425727/files/images/2017/IntelGenx-Product-Portfolio-and-Pipeline-July-2017.jpg
Presentation
http://s2.q4cdn.com/790425727/files/doc_presentations/2017/09/INTELGENX-Presentation-September-2017_final.pdf
https://investorintel.com/sectors/biotech/biotech-intel/intelgenx-thin-film-market/
earnings next week another strong quarter likely then this low float stock should run up fast
Brazilian Dermatology Market Second Largest in the World Behind the United States
PETALUMA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of regulatory approvals by the Brazilian Ministério da Saúde for seven of Sonoma’s non-steroidal and non-antibiotic topical dermatology products:
Gramaderm® Hydrogel – intended as a skin cleanser after treatment of mild to moderate acne.
Gramaderm® – intended as a skin cleanser in a hydrogel vehicle after treatment of mild to moderate acne.
Epicyn™ – intended as a scar treatment.
Pediacyn™ – intended as an atopic dermatitis treatment.
Pediacyn™ Gel – intended as an atopic dermatitis treatment in a gel vehicle.
Lasercyn™ – intended as a skin cleanser following cosmetic procedures such as laser skin resurfacing.
Lasercyn™ Hydrogel – intended as a skin cleanser in a hydrogel vehicle following cosmetic procedures such as laser skin resurfacing.
“My Brazilian counterparts now have treatment options that can either replace or complement the standard protocols. In my practice I use Sonoma’s products for healing and as a steroid-sparing agent, anti-pruritic and anti-inflammatory,” said Dr. Miriam Bettencourt, assistant clinical professor of dermatology at the University of Nevada and adjunct professor of dermatology at Touro University in Las Vegas. “Having studied medicine in Brazil and with many of my colleagues practicing dermatology in Brazil, Sonoma’s new approvals should provide additional non-steroidal and non-antibiotic alternatives much like I use in here in the United States.”
Sonoma Pharmaceuticals is currently seeking to partner with a Brazilian healthcare company relative to licensing these newly approved products in the Brazilian dermatology space.
“We see the Brazilian dermatology market as being highly lucrative in terms of ongoing ramping revenue,” said Bruce Thornton, Sonoma’s VP of international sales. “Brazilian dermatologists are cutting edge when it comes to general dermatology and aesthetic procedures, and the addition of seven new hypochlorous acid-based products provides new alternatives for physicians worried about the side effects of topical steroids and resistance issues with the overuse of antibiotics.”
About the Brazilian Dermatology Market
According to BCC Research, skin conditions are among the most common health problems in most national populations, collectively exceeding the prevalence of conditions such as obesity, hypertension and cancer. The considerable costs of skin diseases include physician visits, hospital care, prescription drugs and over-the-counter products for treating or managing these conditions, as well as indirect costs due to productivity losses.
The global market for skin disease treatment technologies is estimated to reach $20.4 billion in 2020. The U.S market is the largest segment and should reach $8.6 billion in 2020. The BRIC (Brazil, Russia, India, China) countries are the fastest growing region of the global dermatology market and should total more than $4.6 billion by 2020.
Great News out today ...
Sonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Products
https://finance.yahoo.com/news/sonoma-pharmaceuticals-receives-brazilian-approvals-114500685.html
SNOA =Market-Cap $19 M /Cash balance $12.6 M /Shares Out 4.3 M / 17 FDA approvals received to date some of these products are in early launch phase plus additional Product launches expected within 6 months in USA and many more Approvals outside of USA // Annual Revenue on track to hit $16 million// Profitability expected in 2018 . This unknown ultra low float and brutally undervalued stock is a MUST HAVE for everyone who like Pharma stocks .GL
Sonoma Pharma (Nasdaq: SNOA)
Marketcap: 19.6 Million
Cash: $12.6 Million
Price: $4.55
Book Value: $4.32
Annual Revenue on track to hit $16 Million
Shares Out : 4.3 Million
Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) ..October 18, 2017
http://pr.report/78EFCjq0
Fact Sheet
http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
•Mondoxyne for severe acne –launched late 2015
•Ceramax for skin repair in atopic dermatitis–launched in April 2016
•SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017
•Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Regulatory Approvals and Clearances
To date, we have obtained 17 clearances from the U.S. Food and Drug Administration, or FDA, that permit us to sell our products as medical devices for Section 510(k) of the Federal Food, Drug and Cosmetic Act in the United States.
Outside the United Sates, we sell products for dermatological and advanced tissue care with a European Conformity marking (known as Conformité Européenne or CE) covering 25 of our products, and various approvals in Central America, China, Southeast Asia, and the Middle East.
SNOA (MC $19 M) ( $12.6 M) Book Value $4.32 / Annual Revenue on track to hit $16 Million and only 4.3 Million Shares Outstanding this stock is a MASSIVE opportunity .Please do your own dd and realize the mega potential guys .GL
Sonoma Pharma (Nasdaq: SNOA)
Marketcap: 19.6 Million
Cash: $12.6 Million
Price: $4.55
Book Value: $4.32
Annual Revenue on track to hit $16 Million
Shares Out : 4.3 Million
Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) ..October 18, 2017
http://pr.report/78EFCjq0
As of 6/30/17, the Company reported $3.8M in total revenue for Q1 FY18, with product revenues up 49% year-over-year driven by growth in US dermatology and acute care markets and in products sold to new owner of Latin American assets, and with approximately $12.6M in cash on hand and minimal debt. On an EV/R basis, Sonoma currently trades at 0.2x vs. the median of its peers at 34.5x based on FY18 estimates. In addition, companies in the dermatology space have been acquired at a median EV/R multiple of 3.6x. See full report for additional details.
Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis
https://finance.yahoo.com/news/sonoma-pharmaceuticals-announces-u-commercialization-080500194.html
This ultra low float stock is brutally undervalued which tradingjust a few pennies above Book Value .Fantastic entry point here this stock is definitely one of the cheapest in the Pharma Sector .GL
Sonoma Pharma (Nasdaq: SNOA)
Marketcap: 19.6 Million
Cash: $12.6 Million
Price: $4.55
Book Value: $4.32
Annual Revenue on track to hit $16 Million
Shares Out : 4.3 Million
Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) ..October 18, 2017
http://pr.report/78EFCjq0
As of 6/30/17, the Company reported $3.8M in total revenue for Q1 FY18, with product revenues up 49% year-over-year driven by growth in US dermatology and acute care markets and in products sold to new owner of Latin American assets, and with approximately $12.6M in cash on hand and minimal debt. On an EV/R basis, Sonoma currently trades at 0.2x vs. the median of its peers at 34.5x based on FY18 estimates. In addition, companies in the dermatology space have been acquired at a median EV/R multiple of 3.6x. See full report for additional details.
nice jump
Alone the 10 largest shareholders owns almost half of the outstanding shares of 4.2 million which is very strong .
Armistice Capital LLC 405 641
Manchester Management Co. LLC 210 331
JEB Partners LP 200 000
Aigh Partners LP 181 500
Galileo Partners LLC 150 000
JMG Capital Management LLC 116 665
Joshua R. Disbrow, MBA 114 843
Jarrett T. Disbrow, PhD 113 384
Lincoln Park Capital Fund LLC 100 000
Triple Gate Capital GP LLC 100 000
This extreme low float stock can hit $10 very quickly ...
Don't you guys think that Aytu BioSciences Natesto, FDA approved, nasal TRT is far superior to Lipocines Tlando?
https://www.gurufocus.com/news/562122/choosing-wisely-aytu-bioscience-vs-lipocine
this could hit $10 in no time because of its extreme low float .
thats the next one that will go through the roof
P3 Results imminent if positive this low float stock will explode much higher
Completed recruitment of our renal function clinical trial to demonstrate the beneficial effects of KIT-302 on kidney function
Phase 3 results imminent maybe thats the reason
who cares RALLYYYYYYYYYYYYYYYYYYY lol
Up she goes again.. here is older article just to show the big potential ..
Conclusion:In my original article, I ballparked KTOV's valuation at $22.50 per share. That valuation assumed KTOV took KIT-302 to market on its own and therefore, included additional equity financings and a concomitant higher share count on which to base the per share price. It also assumed a weaker marketing capability and therefore, lower peak sales. In this article, I've estimated KTOV's valuation on the idea that it sells KIT-302 to a large pharmaceutical company and I've provided some comparables to ground this valuation. (Nonetheless, there are a lot of assumptions here, particularly the peak sales numbers and the DCF inputs.) The comparable valuation method gives a share price target range of $13 to $29 per share, which corroborates the initial $22.50 per share target. As a result, I continue to hold KTOV as one of my favorite longs, and am hoping for a big payoff within the next four years or so. Indeed, after performing this research, I think it's likely that one of the companies mentioned in the article will buy KTOV sooner rather than later - with Pfizer (Celebrex's developer) being my front-running candidate.
https://seekingalpha.com/article/3939596-kitov-pharmaceuticals-bullish-valuation-based-comparables
AYTU-DD = Market Cap $18 M / Cash $11.8 M / 4 Marketed Products one of them Natesto targeting $2 BILLION Market / Shares Out only 4.22 M ..After doing my dd i can say for sure this unknown stock is a brutal gift at this price .This low float stock should be valued at minimum $120-150 Million (~$30-35 per share ) right now for their marketed products .GL
Market Cap : $18 Million
Cash $11.8 Million
Price $4.20
Shares Out 4.22 Million
Presentation
http://aytubio.com/downloads/Aytu-Corporate-Overview.pdf
Fact Sheet
http://aytubio.com/downloads/Aytu-Corporate-Fact-Sheet.pdf
Marketed Products:
•Natesto–testosterone nasal gel indicated for hypogonadism ($2 billion market in the U.S., 13 million men diagnosed with hypogonadism (low testosterone)
•MiOXSYS–in vitro device for male infertility ($825 million International market ,30 million men impacted in U.S.)
•Fiera–pre-intimacy device to increase sexual desire and arousal in women (53 million women in the U.S. with sexual concerns)
•ProstaScint–imaging agent for prostate cancer
Aytu BioScience (AYTU) Stock: Why This Thing Can Grow Legs!
https://cnafinance.com/aytu-bioscience-aytud-aytu-stock-why-this-thing-can-grow-legs/16622
Aytu BioScience, Inc.(OTCMKTS: AYTU) is a stock that we've covered in great detail as of late, and for good reason. The company is in the prime position to take charge of a massive industry with hundreds of millions if not billions of dollars in potential revenue. Today, we'll get into one of the many reasons that we're so bullish with regard to AYTU, a reason that can be summed up in a single word, Natesto
AYTU-DD = Market Cap $18 M / Cash $11.8 M / 4 Marketed Products one of them Natesto targeting $2 BILLION Market / Shares Out only 4.22 M ..After doing my dd i can say for sure this unknown stock is a brutal gift at this price .This low float stock should be valued at minimum $120-150 Million (~$30-35 per share ) right now for their marketed products .GL
Market Cap : $18 Million
Cash $11.8 Million
Price $4.20
Shares Out 4.22 Million
Presentation
http://aytubio.com/downloads/Aytu-Corporate-Overview.pdf
Fact Sheet
http://aytubio.com/downloads/Aytu-Corporate-Fact-Sheet.pdf
Marketed Products:
•Natesto–testosterone nasal gel indicated for hypogonadism ($2 billion market in the U.S., 13 million men diagnosed with hypogonadism (low testosterone)
•MiOXSYS–in vitro device for male infertility ($825 million International market ,30 million men impacted in U.S.)
•Fiera–pre-intimacy device to increase sexual desire and arousal in women (53 million women in the U.S. with sexual concerns)
•ProstaScint–imaging agent for prostate cancer
Aytu BioScience (AYTU) Stock: Why This Thing Can Grow Legs!
https://cnafinance.com/aytu-bioscience-aytud-aytu-stock-why-this-thing-can-grow-legs/16622
Aytu BioScience, Inc.(OTCMKTS: AYTU) is a stock that we've covered in great detail as of late, and for good reason. The company is in the prime position to take charge of a massive industry with hundreds of millions if not billions of dollars in potential revenue. Today, we'll get into one of the many reasons that we're so bullish with regard to AYTU, a reason that can be summed up in a single word, Natesto .
good summary buddy
We will see $3+ soon especially with partnership for KIT-302 which could happen anytome now .
big breakout could start anytime now
$4.99 day high , looking great so far
If you guys want that the stock moving even faster then put your shares on high GTC sell order like $10 this helps to prevent your shares from being shorted and more important your shares wouldnt be available on the market so if all shareholders doing that then it would help this stock to make bigger jumps in share price on good news. This works good especially on stocks like KTOV which has ony 11 million shares outstanding .Thank you in advance
How to Prevent your Shares Holdings from being Shorted
http://www.contracts-for-difference.com/Borrowing-lending-shares.html
KTOV (Market Cap $20 M ) (Cash $11 M) FDA Decision in Q2 + Phase 3 Results this Q / shares Out only 10.6 Million = Potential 10 bagger and more...GL
Kitov Announces FDA Acceptance of NDA for KIT-302
https://www.baystreet.ca/articles/research_reports/lifesci/Kitov100317.pdf
KIT-302 is a Treatment for Hypertension and Osteoarthritis Pain.
KIT-302 is a fixed dose combination drug comprised of the nonsteroidal anti-inflammatory drug (NSAID)celecoxib, and the well-known antihypertensive agent, amlodipine besylate. Celecoxib
monotherapy often leads to hypertension, which if uncontrolled, can increase the risk of heart attack and stroke. KIT-302 is designed to provide a solution for physicians who avoid prescribing NSAIDs for osteoarthritis pain due to their hypertensive side effects. There is currently no single drug for the treatment of pain and hypertension, so, if approved, KIT-302 could be a unique product in the multibillion-dollar osteoarthritis market.
Expected Upcoming Milestones
¦Q4 2017 – Top-line results from Phase III kidney function trial.
¦Q2 2018 – Expected FDA approval decision for KIT-302.
Kitov Announces FDA Acceptance of NDA for KIT-302
https://www.baystreet.ca/articles/research_reports/lifesci/Kitov100317.pdf
KIT-302 is a Treatment for Hypertension and Osteoarthritis Pain.
KIT-302 is a fixed dose combination drug comprised of the nonsteroidal anti-inflammatory drug (NSAID)celecoxib, and the well-known antihypertensive agent, amlodipine besylate. Celecoxib
monotherapy often leads to hypertension, which if uncontrolled, can increase the risk of heart attack and stroke. KIT-302 is designed to provide a solution for physicians who avoid prescribing NSAIDs for osteoarthritis pain due to their hypertensive side effects. There is currently no single drug for the treatment of pain and hypertension, so, if approved, KIT-302 could be a unique product in the multibillion-dollar osteoarthritis market.
Expected Upcoming Milestones
¦Q4 2017 – Top-line results from Phase III kidney function trial.
¦Q2 2018 – Expected FDA approval decision for KIT-302.
$5 coming closer and closer once we break it then i think the realö run will start .gl
TNXP (MC $33 M) (Cash $34 M) Shares Out 7.5 M // Phase 3 Data in 1H 2018 = 1000%++ UPSIDE Potential !
Ultra Low float Gem / Trading below Cash/ Phase 3 Data in 1H 2018 //$650 Million Potential for the Drug /Stock should be at $15 right now and sky is limit on positive phase 3 outcome = A MUST HAVE .GLTA
Tonix Pharma (TNXP)
Market Cap: $33 Million
Cash: $34.5 Million
Kurs: $4.50
Shares Out: 7.5 Million
New Presentation
http://content.equisolve.net/tonixpharma/media/5834b932b328c4417b28ea179cb3f7c8.pdf
Phase 3 HONOR study of Tonmya in military-related PTSD enrolling
•Encouraging evidence of safety and efficacy was demonstrated in Phase 2
Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA)
•Expedited development and accelerated review are expected
•Potential to file NDA based on one Phase 3 study if data are statistically persuasive
Proposed registration plan agreed by the FDA
•Additional nonclinical safety and clinical abuse potential studies are not required
Patent protection through 2034 in U.S.
•Composition of matter patent for eutectic, required for transmucosal delivery of cyclobenzaprine
Another good day but real jump will start once we hit the $5 mark because many Institutions who are not allowed to buy stock under $5 will start jump in . Stock is still a gift here trading at Cash and with a advanced Phase 3 program close to readout .GL
still a mega opportunity here guys ...